Last reviewed · How we verify
Alba Maria Ropero — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Co-administration of MMR/YF | Co-administration of MMR/YF | marketed | vaccine | Immunology | ||
| YF followed by MMR | YF followed by MMR | marketed | ||||
| MMR followed by YF | MMR followed by YF | marketed | Live attenuated viral vaccine combination | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology · 1
- Immunology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Aduro Biotech, Inc. · 1 shared drug class
- Aeras · 1 shared drug class
- Aga Khan University · 1 shared drug class
- Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
- Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- ANRS, Emerging Infectious Diseases · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Alba Maria Ropero:
- Alba Maria Ropero pipeline updates — RSS
- Alba Maria Ropero pipeline updates — Atom
- Alba Maria Ropero pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Alba Maria Ropero — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alba-maria-ropero. Accessed 2026-05-17.